59.54

6.16% -3.91

After Hours: 59.54

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $59.54, with a volume of 2.89M. It is down -6.16% in the last 24 hours and down -10.55% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$63.45

Open:

$62.82

24h Volume:

2.89M

Relative Volume:

1.42

Market Cap:

$9.32B

Revenue:

$1.22B

Net Income/Loss:

$77.95M

P/E Ratio:

121.71

EPS:

0.4892

Net Cash Flow:

$224.06M

1W Performance:

-9.60%

1M Performance:

-10.55%

6M Performance:

+12.70%

1Y Performance:

-11.71%

1-Day Range:

$58.04

$63.45

1-Week Range:

$58.04

$67.60

52-Week Range:

$46.01

$72.16

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

612-379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,100

Twitter

@biotechne

Next Earnings Date

2024-10-30

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	59.54	9.93B	1.22B	77.95M	224.06M	0.4892
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-21-25	Upgrade	Citigroup	Neutral → Buy
Jul-22-25	Resumed	Stephens	Overweight
Jul-09-25	Initiated	TD Cowen	Buy
May-30-25	Initiated	Wells Fargo	Overweight
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

Feb 11, 2026

(TECH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Feb 11, 2026

5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call - Finviz

Feb 11, 2026

There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings - Yahoo Finance

Feb 11, 2026

Madison Asset Management LLC Acquires Shares of 744,651 Bio-Techne Corp $TECH - MarketBeat

Feb 11, 2026

Bio-Techne (NASDAQ:TECH) Stock Rating Upgraded by Zacks Research - MarketBeat

Feb 11, 2026

Bio-Techne Corp (NASDAQ:TECH) Passes Key Quality Investing Screen - ChartMill

Feb 11, 2026

Baader Bank Aktiengesellschaft Buys 38,082 Shares of Bio-Techne Corp $TECH - MarketBeat

Feb 11, 2026

Bio-Techne: How Spatial Biology Innovation Is Powering a Strategic Comeback! - Smartkarma

Feb 11, 2026

Feb 10, 2026

Azzad Asset Management Inc. ADV Has $774,000 Stock Holdings in Bio-Techne Corp $TECH - MarketBeat

Feb 10, 2026

Feb 09, 2026

How Flat Sales, Higher EPS, and New Organoid Tools At Bio-Techne (TECH) Have Changed Its Investment Story - Yahoo Finance

Feb 09, 2026

Feb 07, 2026

Bio-Techne stock price target raised to $65 from $60 at Stifel By Investing.com - Investing.com Nigeria

Feb 07, 2026

New York State Common Retirement Fund Sells 465,634 Shares of Bio-Techne Corp $TECH - MarketBeat

Feb 07, 2026

Feb 06, 2026

Bio-Techne stock price target raised to $65 from $60 at Stifel - Investing.com UK

Feb 06, 2026

Wells Fargo & Company Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price - MarketBeat

Feb 06, 2026

TECH Stock Update: Wells Fargo Raises Price Target for Bio-Techne | TECH Stock News - GuruFocus

Feb 06, 2026

Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Cor - GuruFocus

Feb 06, 2026

Feb 05, 2026

Bio-Techne (TECH) Sees Target Price Raised by Stifel | TECH Stoc - GuruFocus

Feb 05, 2026

UBS Maintains Buy Rating on Bio-Techne (TECH) with Raised Price Target | TECH Stock News - GuruFocus

Feb 05, 2026

Citigroup Raises Price Target for Bio-Techne (TECH) to $80.00 | - GuruFocus

Feb 05, 2026

7 Analysts Assess Bio-Techne: What You Need To Know - Benzinga

Feb 05, 2026

Assessing Bio-Techne (TECH) Valuation After Earnings Beat And New Research Product Launches - simplywall.st

Feb 05, 2026

Tech Stock Update: Evercore ISI Group Raises Price Target for TE - GuruFocus

Feb 05, 2026

TD Cowen Maintains Buy Rating on Bio-Techne (TECH) and Raises Pr - GuruFocus

Feb 05, 2026

Leerink Partners Adjusts Price Target on Bio-Techne to $80 From $75, Maintains Outperform Rating - marketscreener.com

Feb 05, 2026

Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript - Insider Monkey

Feb 05, 2026

Techne Corp. (TECH) Q2 Earnings Report: Results Top Analyst ForecastsNews and Statistics - IndexBox

Feb 05, 2026

TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets - Finviz

Feb 05, 2026

Feb 04, 2026

Trading Recap: Is Bio Techne Corporation showing insider buying2025 Analyst Calls & Advanced Technical Signal Analysis - baoquankhu1.vn

Feb 04, 2026

Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales - The Globe and Mail

Feb 04, 2026

Bio-Techne Corp Plans Quarterly Dividend of $0.08 (NASDAQ:TECH) - MarketBeat

Feb 04, 2026

Bio-Techne Releases Second Quarter Fiscal 2026 Results - Investing News Network

Feb 04, 2026